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ARSTRACT 
Objectives: Crusted (Norwegian) scabies is an unusual variant 
of scabies caused by hyperinfestation with Sarcoptes scabiei. 
It has high morbidity, and secondary bacterial skin sepsis may 
result in life-threatening bacteremia. An open label study of oral 
ivermectin was carried out in patients with crusted scabies 
refractory to topical therapy. 
Methods: Patients with refractory crusted scabies were pre- 
scribed oral ivermectin, one to three doses of 200 pg/kg at 
14.day intervals, combined with topical scabicide and kera- 
tolytic therapy. 
Results: Of the 20 patients who received ivermectin, 8 had a 
complete initial clinical response, a partial response was 
achieved in 9, and minimal improvement occurred in 3. Three 
doses of ivermectin were curative for 8 of 10 cases, but recur- 
rence of scabies from presumed reinfestation occurred in at 
least half of these. 
Conclusion: The authors conclude that ivermectin is effective 
for crusted scabies; however, multiple doses may be required 
to achieve a cure, and recurrence 6 or more weeks after com- 
pleting treatment is common. 
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Crusted or Norwegian scabies is an unusual variant of sca- 
bies first described in a group of leprosy patients in Nor- 
way. It is caused by hyperinfestation with Sarcoptes 
scabiei and is characterized by hyperkeratosis, scaling, 
and crusted lesions over a wide distribution of the body 
It is usually seen in association with underlying predis- 
posing conditions, including human immunodeficiency 
virus (HIV), hematologic malignancy, immunosuppressive 
therapy, connective tissue diseases, and neurologic illness.’ 
*Royal Darwin Hospital, Menzies School of Health Research, Darwin, 
Northern Territory, Australia. 
Received: June 9, 1997; Accepted: December 4, 1997. 
Address correspondence to Assoc. Prof. Bart J. Currie, Menzies School 
of Health Research, PO. Box 41096, Casuarina Northern Territory, 0811 
Australia. 
Scabies is endemic in many remote aboriginal com- 
munities of Australia with prevalence in children up to 
50%.* Crusted scabies has been associated with human 
T-cell lymphotropic virus type I (HTLV-I) in central Aus- 
tralia.3 In remote aboriginal communities in the tropical 
north of the Northern Territory, HTLV-I is not endemic, 
and HIV has not been documented in that region. The 
majority of aboriginal patients with crusted scabies in 
these communities have no identified specific immuno- 
suppression.’ Crusted scabies has a high morbidity and 
secondary bacterial skin sepsis may result in life-threat- 
ening bacteremia.4 It is highly infectious and may cause 
widespread outbreaks of scabies.5 
Therapy is usually with topical scabicides, but success 
with crusted scabies is often limited. Ivermectin is a 
chemically modified avermectin, a class of antiparasitic 
agents produced by the actinomycete Streptomyces 
avermitilis. It has a broad spectrum of activity against 
nematodes (excluding human hookworm) and arthropod 
parasites. It is used widely as an antiparasitic drug in vet- 
erinary practice, including for sarcoptic mange.6 Iver- 
mectin has been used in humans most extensively for 
onchocerciasis and more recently for strongyloides infec- 
tion.’ There has been some success with this drug against 
human scabies infestation, including in crusted scabies.*z9 
The authors performed an open label study of 22 
patients from the tropical north of the Northern Territory 
with crusted scabies refractory to topical therapy, who 
were prescribed ivermectin for compassionate use in a 
protocol adapted from the regimen of Meinking et a1.7 
MATERIAL AND METHODS 
The diagnosis of crusted scabies was made on clinical 
findings plus positive skin scrapings for S. scabiei mites. 
All patients had crusted lesions that had inadequately 
responded to multiple topical scabicide treatments. Man- 
agement in most cases involved hospitalization for at least 
1 week and an intensive regimen of topical therapy with 
three supervised applications of permethrin 5% topical 
scabicide, spaced over the week, the cream being applied 
from the scalp down, left overnight, and washed off the 
following morning. On the days when permethrin was 
not used, keratolytic therapy with urea lo%, and lactic 
acid 5% cream was applied. Oral ivermectin was given on 
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an empty stomach at a single dose of 200 pg/kg, and in 
most cases subsequent doses of ivermectin were planned 
for day 14 and day 28. Administration of this medication, 
supervision of further topical therapy, and environmen- 
tal control measures, such as treatment of household con- 
tacts, advice regarding washing of linen and clothes, and 
fumigation of the house with synthetic pyrethroid-con- 
taining insecticide, were done through the health clinic 
in the patient’s community Responses to treatment were 
judged on clinical assessment of the skin and were graded 
as minimal, partial, or complete. As the full effect of sca- 
bies therapy may not be evident for several weeks,9 a 
complete response was defined as normal skin 4 weeks 
or longer after the last dose of ivermectin. Whereas recur- 
rence after partial response was assumed to be recrude- 
scence of the original scabies infestation, recurrence after 
complete response was assumed to be reinfestation. 
Fisher’s exact test was used to compare outcomes of 
therapy. 
Table 1. Number of Doses of lvermectin 
Received and Clinical Response 
Response One Dose Two Doses Three Doses* 
Complete 0 3 8 
Partial 5 2 2 
Minimal 3 2 0 
*Complete response versus minimal or partial response was significantly greater 
for three doses than for one or two doses of ivermectin; P = 0.005, Fisher’s 
exact test. 
crusted scabies. This last patient has had a total of 10 
ivermectin doses over 12 months. 
Of the 25 treatment courses given to 20 patients, 
there was significantly better clinical response in those 
who received three doses of ivermectin (Table l), but in 
two cases even three doses of ivermectin was not cura- 
tive. One man who had a partial response after only one 
dose of ivermectin received a full course of three doses 
of ivermectin 1 year later, with complete response. No 
adverse effects of the drug were observed. 
RESULTS 
DISCUSSION 
The patients were aboriginal (12 male and 10 female) 
and between 21 and 76 years of age (mean, 42.8 y). 
Crusted lesions involved all four limbs and the trunk, in 
the majority, and skin scrapings invariably showed numer- 
ous S. scabiei mites. Most had documented clinical sca- 
bies for over 1 year, the longest being for 12 years. Eight 
patients had been admitted to hospital at least once, and 
one patient had been admitted 12 times for secondary 
sepsis. Two patients who were intended to be treated 
died prior to receiving ivermectin. One was a 35-year-old 
woman who died of polymicrobial sepsis and the other, 
a 51-year-woman with a history of treated leprosy, who 
died following amputation of a severely infected arm. 
Preceding conditions included treated leprosy in two, 
noninsulin-dependent diabetes in three, and steroid ther- 
apy for chronic lung disease in one. There was no evi- 
dence of HIV in 14 patients tested or HTLV-I in 13 
patients, with both viruses not known to be present in 
any of the communities involved. No underlying malig- 
nancies were detected. 
A complete initial response was achieved in 8 of 20 
(40%) patients, 9 of 20 (45%) had at least a partial 
response (3 of these possibly had a complete response, 
but this was not confirmed) and 3 of 20 (15%) had min- 
imal improvement after ivermectin therapy. Four of the 
eight patients with a complete initial response had recur- 
rence of scabies, occurring 6 to 40 weeks after the last 
ivermectin dose and usually progressing to crusted sca- 
bies. Two of these were retreated, with again a complete 
response, but both had further recurrence 8 and I6 
weeks after ivermectin. One of these had a third treat- 
ment course, but again developed recurrent severe 
In uncomplicated scabies, single-dose ivermectin was 
found to be at least as effective as topical therapy.‘O As 
noted by Meinking et al, reported “treatment failures” may 
be explained by the sometimes slow resolution of skin 
signs after therapy or by reinfestation after ivermectin 
tissue activity has ceased.9 The authors’ observations of 
empirical therapy of crusted scabies with ivermectin sup- 
port the findings of Meinking et al that single dose iver- 
mectin may be inadequate with severe scabies 
hyperinfestation and that further, second weekly doses 
are beneficial in such cases.9 Whether more frequent dos- 
ing or doses higher than 200 kg/kg will have better out- 
comes requires further study. The concomitant use of 
topical scabicides and keratolytics seems justified by 
concerns that ivermectin may not penetrate thick crusts 
adequately.2 
With one or two doses of ivermectin, a partial 
response was often followed by deterioration, suggest- 
ing recrudescence after failure to eradicate parasites. 
While three doses usually resulted in a complete clinical 
response, recurrent scabies commonly occurred 6 or 
more weeks after therapy. With the high prevalence of 
scabies in these communities, reinfestation is not sur- 
prising. Currently, molecular typing methods for Sxabiei 
are being developed, to better define recrudescence ver- 
sus reinfestation following scabies therapies.ll Although 
regularly repeated or intermittent ivermectin therapy may 
be of benefit for individuals with recurrent crusted 
scabies, emphasis should be placed on coordinated entire- 
community interventions to break the cycles of trans- 
mission of S. scabiei that lead to infestation.12 
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